Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
After an interim overall survival readout last year shook investor confidence, Akeso has claimed victory Thursday with updated Phase 3 data for its closely watched PD-1xVEGF bispecific in certain lung cancer patients. Akeso said ivonescimab ...
Akeso has announced that its Phase 3 trial for ivonescimab, a PD-1xVEGF bispecific, met the key secondary endpoint of overall survival (OS) in certain lung cancer patients. According to Vietnam Investment Review, the trial, called HARMONi-2, compared ivonescimab to pembrolizumab as a first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1.
The results showed that ivonescimab demonstrated a statistically significant and clinically meaningful improvement in OS over pembrolizumab. This is a notable achievement, as the HARMONi-2 study is the first randomized, double-blind Phase III trial to show a significant positive outcome against pembrolizumab in this setting.
In a previous analysis in May 2024, ivonescimab had already met its primary endpoint of progression-free survival (PFS), with a median PFS of 11.14 months compared to 5.82 months for pembrolizumab, as per Vietnam Investment Review. Detailed data from the interim OS analysis will be presented at an upcoming international medical conference and published in a peer-reviewed journal.
Brief written by urgent.news from Endpoints News, Vietnam Investment Review — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
